PLAUR and chronic kidney disease: One such factor, a soluble urokinase plasminogen activator receptor (suPAR) associated with chronic kidney disease (CKD)17, was recently shown to synergize preferentially with G1 or G2 variants for activation of αvβ3 integrin signaling pathway, triggering podocyte injury18.